Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag added to horse ATG plus cyclosporine for front-line severe aplastic anemia
NL-OMON44180Phase 3Active, not recruiting
- Sponsor
- EBMT
- Start
- Feb 2016
- Modality
- Small Molecules, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eltrombopag, antilymphocyte immunoglobulin (horse) and cyclosporine in aplastic anemia (2 arms), sponsored by EBMT. Primary endpoint: Complete response rate at 3 months. Started Feb 2016; status: active, not recruiting.
02
Drugs
eltrombopagantilymphocyte immunoglobulin (horse)cyclosporine
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NL-OMON44180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44180.